■本荟萃分析的目的是评估熊去氧胆酸(UDCA)在非酒精性脂肪性肝病(NAFLD)治疗中的有效性。
■电子数据库,如PubMed,Embase,Scopus,和CochraneLibrary彻底寻找确定熊去氧胆酸(UDCAs)对NAFLD患者血清肝功能测试有效性的随机对照试验。筛选后,共纳入7项随机对照试验.利用固定效果模型,在R版本4.3.1中进行了定量数据合成.
■荟萃分析显示丙氨酸转氨酶(ALT)显着降低(p≤0.0001),天冬氨酸转氨酶(p=0.0009),UDCA治疗后的γ-谷氨酰转移酶(GGT)(p≤0.0001)。然而,未发现胆红素(p=0.6989)和碱性磷酸酶(ALP)(p=0.1172)水平显著下降.通过消除一些偏倚的研究,敏感性分析成功地证明了天冬氨酸转氨酶和ALP的异质性显着降低。在通过剂量进行亚组分析时也观察到了这一点。
■熊去氧胆酸对诊断为NAFLD的患者有益,因为它显著降低了天冬氨酸转氨酶,ALT和GGT水平。然而,未来需要进行更多的随机对照试验,以提高明显发现的确定性.
■这项荟萃分析加强了关于AST降低的证据,ALT,和GGT水平观察到熊去氧胆酸治疗NAFLD患者通过汇集数据从最新的RCTs,从而证明其肝脏保护作用,可有利于预防相关并发症。
■帕特尔VS,马哈茂德SF,BhattKH,etal.熊去氧胆酸治疗非酒精性脂肪性肝病的有效性:系统评价和Meta分析。欧亚J肝胃肠病2024;14(1):92-98。
UNASSIGNED: This meta-analysis\'s objective was to assess the effectiveness of ursodeoxycholic acid (UDCA) in the management of nonalcoholic fatty liver disease (NAFLD).
UNASSIGNED: Electronic databases like PubMed, Embase, Scopus, and Cochrane Library were thoroughly looked for randomized controlled trials determining ursodeoxycholic acid\'s (UDCAs) effectiveness on the serum liver function tests in NAFLD patients. After screening, seven randomized controlled trials were incorporated overall. Utilizing a fixed effects model, quantitative data synthesis was performed in R version 4.3.1.
UNASSIGNED: The meta-analysis showed significant reductions in alanine transaminase (ALT) (p ≤ 0.0001), aspartate transaminase (p = 0.0009), and gamma-glutamyl transferase (GGT) (p ≤ 0.0001) after UDCA therapy. However, significant reductions in bilirubin (p = 0.6989) and alkaline phosphatase (ALP) (p = 0.1172) levels were not noted. Sensitivity analysis by removing the studies with some concerns of bias was successful in demonstrating a remarkable reduction in heterogeneity for aspartate transaminase and ALP, which was also observed while performing the subgroup analyses via dosage.
UNASSIGNED: Ursodeoxycholic acid was beneficial in patients diagnosed with NAFLD as it significantly reduced aspartate transaminase, ALT and GGT levels. However, more randomized controlled trials are required to be conducted in the future to increase the certainty of the evident findings.
UNASSIGNED: This meta-analysis strengthens the evidence about the reductions in AST, ALT, and GGT levels observed with ursodeoxycholic acid therapy in NAFLD patients by pooling the data together from the latest RCTs thus proving its hepatoprotective effects which can be beneficial in preventing the associated complications.
UNASSIGNED: Patel VS, Mahmood SF, Bhatt KH, et al. Ursodeoxycholic Acid\'s Effectiveness in the Management of Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis. Euroasian J Hepato-Gastroenterol 2024;14(1):92-98.